Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma

Hepatology

Volumn 62, Issue 4, 2015, Pages 1160-1173

  Won, Cheolhee ^a   Kim, Byung Hak ^a   Yi, Eun Hee ^a   Choi, Kyung Ju ^b   Kim, Eun Kyung ^c   Jeong, Jong Min ^d   Lee, Jae Ho ^e   Jang, Ja June ^a   Yoon, Jung Hwan ^a   Jeong, Won Il ^d   Park, In Chul ^f   Kim, Tae Woo ^g   Bae, Sun Sik ^c   Factor, Valentina M ^h   Ma, Stephanie ⁱ   Thorgeirsson, Snorri S ^h   Lee, Yun Han ^b   Ye, Sang Kyu ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Kwandong University College of Medicine   (South Korea)

^f Korea Institute of Radiation and Medical Science   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TUMOR PROMOTION; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; LIVER NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PEPTIDES; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84942551966     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27968     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
3. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:161-173.
4. Yamashita T, Wang WX. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-1918.
5. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556.
6. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-1218.
7. Yu H, Jove R. The status of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
8. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;1:6613-6626.
9. Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012;55:108-120.
10. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2008;48:1528-1539.
11. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A 2008;105:2445-2450.
12. + liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011;9:50-63.
13. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-665.
14. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol 2005;175:6257-6263.
15. Kockar F, Yildrim H, Sagkan RI, Hagemann C, Soysal Y, Anacker J, et al. Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. World J Clin Oncol 2012;3:82-91.
16. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
17. D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P, Bonafé M. Epigenetic control of the basal-like gene expression profile via interleukin-6 in breast cancer cells. Mol Cancer 2010;9:300.
18. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009;28:3949-3959.
19. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007;81:10249-10257.
20. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49:S56-S60.
21. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556.
22. Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci 2014;16:159-177.
23. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007;4:536-550.
24. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010;16:5189-5199.
25. Liu LP, Ho RL, Chen GG, Lai PB. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 2012;18:5662-5671.
26. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006;203:18154-18159.
27. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated STAT3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-293.
28. Przewloka MR, Venkei Z, Bolanos-Garcia VM, Debski J, Dadlez M, Glover DM. CENP-C is a structural platform for kinetochore assembly. Curr Biol 2011;21:399-405.
29. Samora CP, Mogessie B, Conway L, Ross JL, Straube A, McAinsh AD. MAP4 and CLASP1 operate as a safety mechanism to maintain a stable spindle position in mitosis. Nat Cell Biol 2011;13:1040-1050.
30. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095-5102.
31. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7:694-707.
32. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-820.
33. Won C, Lee CS, Lee JK, Kim TJ, Lee KH, Yang YM, et al. CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. Anticancer Res 2010;30:481-488.
34. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
35. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol 2010;8:147.
36. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009;50:1861-1870.
37. Huang S, Sincrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010;9:742-750.
38. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-271.
39. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991;24:457-461.